| Similar Articles |
|---|
 |
The Motley Fool
March 1, 2007
Brian Lawler |
Hospira's Boring Growth The medical products provider announces its fourth quarter financial results and gives guidance for 2007. Investors, take note.   |
The Motley Fool
August 10, 2006
Stephen D. Simpson |
Volatility, Thy Name Is Hospira Margins continue to stand in the way of consistent performance at the health-care company. Investors, take note. |
The Motley Fool
September 22, 2006
Brian Lawler |
Hospira's New Mate Down Under The specialty injectable pharmaceutical announces an acquisition, but the move means adding on a lot more debt. Investors, take note. |
The Motley Fool
May 9, 2006
Stephen D. Simpson |
Riding the Hospira Yo-Yo There's a solid foundation on this roller coaster pharmaceutical and drug delivery company. Maybe Hospira's current valuation doesn't make it a "gem," but that's not really within its control. |
The Motley Fool
November 10, 2005
Stephen D. Simpson |
Hospitable Treatment for Hospira Solid margins fuel strong earnings at the hybrid generics - medical distributor. Buying this stock wisely may be the key to good long-term returns. |
The Motley Fool
November 11, 2004
Brian Gorman |
Hospira's Possibilities The medical products and services outfit is not flashy, but it may benefit from long-term trends. Their stock may be worth monitoring. |
The Motley Fool
November 9, 2006
Brian Lawler |
Hospira's Flatlining Sales There's no good news to be found in this medical products supplier's medicine chest. The upcoming fourth quarter isn't going to be any better, either. Investors, take note. |
The Motley Fool
June 2, 2005
Brian Gorman |
Hospira's Little Purchase There may be more to Hospira's recent acquisition than meets the eye. |
The Motley Fool
May 13, 2005
Brian Gorman |
Hospira's Hopeful Signs The medical products company's strong quarter belies a less exciting future. Investors should probably take a wait-and-see attitude. |
The Motley Fool
January 20, 2011
Jeremy Phillips |
Time to Sell Hospira? Hospira has failed two of the quick tests that would make it a sell. This is great, but does it mean you should hold your Hospira shares? |
The Motley Fool
November 9, 2005
Stephen D. Simpson |
Fishing for Value at Fisher Even with today's earnings-induced jump, there still might be some value here at researcher Fisher Scientific. Investors, take note. |
BusinessWeek
May 31, 2004
Robert Barker |
Hospira Just May Put You In The Pink If the Abbott Laboratories spin-off's first steps hardly seem promising, that's one reason why I see the company as worth much more of the intelligent investor's attention than the long calendar of pending tech and biotech IPOs. |
The Motley Fool
March 1, 2006
Brian Gorman |
Hospira's Stumble In spite of an unsightly quarter, good things still are happening at this medical products and services outfit. Investors, take note. |
The Motley Fool
December 15, 2010
Seth Jayson |
Does This Mean Hospira Will Burn You? Investors should watch Hospira's top line carefully during the next quarter or two. |
The Motley Fool
October 20, 2005
Stephen D. Simpson |
Baxter Needs Growth Infusion This is a fine health-care company, but a sluggish top line suggests there are limits to how far it can go. Trading at nearly 20 times forward earnings, it seems like expectations of a growth revival are already in the stock. |
The Motley Fool
January 5, 2010
Brian Orelli |
A Deal Manufactured by Necessity Genzyme gets some help from a new friend. |
The Motley Fool
February 11, 2010
Brian Orelli |
A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid. |
The Motley Fool
July 8, 2010
Selena Maranjian |
Get 2-for-1 Stock-Price Growth This one-two punch can lead to serious gains. Stocks that offer both earnings growth and P/E growth can help you rack up knockout returns over the long haul. |
The Motley Fool
November 20, 2006
Brian Gorman |
Hospira's Bold Move The drug delivery outfit's stab at biosimilars is worth some attention, but investors shouldn't assume a major payoff. |
The Motley Fool
April 18, 2008
Brian Orelli |
Recalls Can't Beat Baxter In spite of charges for two recalls, Baxter posts a decent quarter. |
The Motley Fool
July 19, 2005
Stephen D. Simpson |
Peek-a-Boo ICU ICU Medical has taken on quite a bit of risk in the process of remaking the company. It's best to wait for a reasonable valuation before buying shares. |
Chemistry World
February 12, 2015
Rebecca Trager |
Hospira buyout is a shot in the arm for Pfizer's biosimilars Pfizer said in a statement that its acquisition of Hospira will create 'a leading global sterile injectables business. |
The Motley Fool
February 23, 2004
Brian Gorman |
Abbott Cleans Up Its Act Abbott closes the books on its problems with the FDA and clears the way to a spinoff. Abbott finally passed FDA muster with its Illinois diagnostics plant. Its multi-year problem highlights the importance of investors monitoring manufacturing while watching a pharmaceutical company's pipeline. And with its FDA compliance issues behind it, Abbott can look forward to spinning off its Hospital Products Division. |
The Motley Fool
July 9, 2004
Phil Wohl |
Abbott Labs Concocts Strong Q2 The drug maker reports earnings as expected and refines its third-quarter guidance. |
The Motley Fool
July 8, 2008
Brian Orelli |
Now That's the Way to Spin Off a Company The two spin-off companies formed from Abraxis Pharmaceutical, APP Pharmaceuticals and Abraxis BioScience, are worth almost double the value their parent had before the sale. |
IndustryWeek
June 1, 2007
Traci Purdum |
500 Largest U.S. Manufacturers: Manufacturing Giants This group of manufacturing leaders is demonstrating how to stay competitive in a global economy. |
IndustryWeek
September 1, 2006
David Blanchard |
Hospira CEO Chris Begley -- Diagnosis: Green and Lean Chris Begely says manufacturers should become more environmentally responsible. What's more, he's doing something about it. |
The Motley Fool
November 27, 2006
Brian Lawler |
Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs. |
The Motley Fool
September 2, 2009
Brian Orelli |
Should You Buy This Spinoff? Cardinal Health kicks its baby out of the nest. |
BusinessWeek
January 29, 2007
Michael Arndt |
Abbot Labs: Diagnosis: Shrewd Moves Abbott Laboratories has announced that it is selling about two-thirds of its $4 billion diagnostics business to buy more medical products outfits to help boost overall sales and profits by at least 10% a year into the next decade. |
The Motley Fool
September 30, 2008
Brian Orelli |
Cardinal Health Clips Its Wings Does it make sense for the drug wholesaler to spin off its medical equipment business? |
The Motley Fool
March 10, 2008
Brian Orelli |
Breakup Weighs Down APP It's going to take awhile for APP Pharmaceuticals to reward investors. |
